Answers are grounded in this paper and cite their sources.
TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?To the Editors:The emergence of multidrug-resistant (MDR) tuberculosis (TB), defined as in vitro resistance to isoniazid and rifampicin, and extensively drug-resistant (XDR)-TB, defined as in vitro drug resistance to isoniazid and rifampicin plus any fluoroquinolone and at least one of the injectable drugs (amikacin, capreomycin or kanamycin), represents a major threat to TB control at the global level [1-5].XDR-TB is a manmade product, resulting, in essence, from clinical mismanagement of newly diagnosed susceptible and resistant TB cases [2-5].Moreover, existing MDR/XDR-TB cases must be promptly detected and treated, and the transmission from infectious source cases has to be prevented, particularly in nosocomial settings [2][3][4][5][6].
No takes yet. Share an insight, caveat, or question.
Sotgiu et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: